- Home
- BSL vs PLX Comparison
BSL vs PLX Comparison
Compare BSL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSL
- PLX
- Stock Information
- Founded
- BSL 2010
- PLX 1993
- Country
- BSL United States
- PLX Israel
- Employees
- BSL N/A
- PLX N/A
- Industry
- BSL Trusts Except Educational Religious and Charitable
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSL Finance
- PLX Health Care
- Exchange
- BSL Nasdaq
- PLX Nasdaq
- Market Cap
- BSL 186.5M
- PLX 160.2M
- IPO Year
- BSL N/A
- PLX 1998
- Fundamental
- Price
- BSL $14.11
- PLX $2.57
- Analyst Decision
- BSL
- PLX Strong Buy
- Analyst Count
- BSL 0
- PLX 1
- Target Price
- BSL N/A
- PLX $15.00
- AVG Volume (30 Days)
- BSL 71.9K
- PLX 791.9K
- Earning Date
- BSL 01-01-0001
- PLX 03-17-2025
- Dividend Yield
- BSL 9.55%
- PLX N/A
- EPS Growth
- BSL N/A
- PLX N/A
- EPS
- BSL N/A
- PLX 0.04
- Revenue
- BSL N/A
- PLX $53,399,000.00
- Revenue This Year
- BSL N/A
- PLX $67.17
- Revenue Next Year
- BSL N/A
- PLX $55.31
- P/E Ratio
- BSL N/A
- PLX $69.84
- Revenue Growth
- BSL N/A
- PLX N/A
- 52 Week Low
- BSL $12.19
- PLX $0.82
- 52 Week High
- BSL $14.56
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- BSL 42.72
- PLX 58.33
- Support Level
- BSL $14.07
- PLX $2.24
- Resistance Level
- BSL $14.23
- PLX $2.62
- Average True Range (ATR)
- BSL 0.09
- PLX 0.15
- MACD
- BSL 0.02
- PLX 0.03
- Stochastic Oscillator
- BSL 33.33
- PLX 82.08
About BSL Blackstone
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage, which may increase the risk to the Fund.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.